Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review
Significant operating cost and workforce reductions estimated to lower operational expenses by approximately $18 million in 2018
View HTML
Toggle Summary Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer
VANCOUVER, British Columbia , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Michael Price as senior vice
View HTML
Toggle Summary Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice
VANCOUVER, British Columbia , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that District Judge William Young rejected
View HTML
Toggle Summary Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change
Company Reiterates FY 2017 Guidance for Total Net Revenues of $135-$145 million Company Announces Leadership Change and Search for Chief Executive Officer VANCOUVER, British Columbia , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated
View HTML
Toggle Summary Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer
VANCOUVER, British Columbia , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Jeffrey Hackman as Executive
View HTML
Toggle Summary Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D
VANCOUVER, British Columbia , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Murray Stewart , M.D.
View HTML
Toggle Summary Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH
View HTML
Toggle Summary Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Sept. 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of two separate
View HTML
Toggle Summary Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
VANCOUVER, British Columbia , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Suzanne Bruhn , Ph.D.
View HTML
Toggle Summary Novelion Therapeutics Reports Second Quarter 2017 Financial Results
MYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time Adjustments Global Expansion Plans for Metreleptin Opportunity Underway Company Updates Guidance for FY 2017 Total Net Revenues Conference call to be held today at 8:30 a.m. ET VANCOUVER , Aug.
View HTML